Search research articles
Contact Us
Filters
Showing results (81-90 of 120) with videos related to
Page
of 12
Sort By:
Oral Oncology
|
January 14, 2024
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma
Sankar Jagadeeshan, Kushal Suryamohan, Nara Shin, et al.
Thyroid : Official Journal of the American Thyroid Association
|
January 20, 2022
Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial
Vatche Tchekmedyian, Lara Dunn, Eric Sherman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2016
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer
Martin G Dalin, Alexis Desrichard, Nora Katabi, et al.
The Journal of Clinical Investigation
|
August 10, 2023
Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
Cristina Valero, Mahdi Golkaram, Joris L Vos, et al.
Nature Communications
|
November 1, 2017
Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions
Martin G Dalin, Nora Katabi, Marta Persson, et al.
CA: a Cancer Journal for Clinicians
|
October 28, 2022
Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer
Jung Julie Kang, Yao Yu, Linda Chen, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2021
Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations
Alan L Ho, Irene Brana, Robert Haddad, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 27, 2018
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Lara A Dunn, Eric J Sherman, Shrujal S Baxi, et al.
Cancer Research
|
June 20, 2023
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
Alison E Smith, Stacia Chan, Zhiyong Wang, et al.
Page
of 12
Search research articles
Search
Showing results (81-90 of 120) with videos related to
Sort By:
Page
of 12
Oral Oncology
|
January 14, 2024
Evolutionary dynamics of tipifarnib in HRAS mutated head and neck squamous cell carcinoma
Sankar Jagadeeshan, Kushal Suryamohan, Nara Shin, et al.
Thyroid : Official Journal of the American Thyroid Association
|
January 20, 2022
Enhancing Radioiodine Incorporation in <i>BRAF</i>-Mutant, Radioiodine-Refractory Thyroid Cancers with Vemurafenib and the Anti-ErbB3 Monoclonal Antibody CDX-3379: Results of a Pilot Clinical Trial
Vatche Tchekmedyian, Lara Dunn, Eric Sherman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 23, 2016
Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer
Martin G Dalin, Alexis Desrichard, Nora Katabi, et al.
The Journal of Clinical Investigation
|
August 10, 2023
Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
Cristina Valero, Mahdi Golkaram, Joris L Vos, et al.
Nature Communications
|
November 1, 2017
Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions
Martin G Dalin, Nora Katabi, Marta Persson, et al.
CA: a Cancer Journal for Clinicians
|
October 28, 2022
Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer
Jung Julie Kang, Yao Yu, Linda Chen, et al.
Investigational New Drugs
|
March 11, 2017
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel
Lillian M Smyth, Kelsey R Monson, Komal Jhaveri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 22, 2021
Tipifarnib in Head and Neck Squamous Cell Carcinoma With <i>HRAS</i> Mutations
Alan L Ho, Irene Brana, Robert Haddad, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 27, 2018
Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers
Lara A Dunn, Eric J Sherman, Shrujal S Baxi, et al.
Cancer Research
|
June 20, 2023
Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhibition in PIK3CA- and HRAS-Dysregulated HNSCC via Convergent Inhibition of mTOR Activity
Alison E Smith, Stacia Chan, Zhiyong Wang, et al.
Page
of 12